Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Ignyta, Inc
Woman and Man Max 99 years
Ignyta, Inc
Update Il y a 4 ans
A clinical study to investigate the safety and efficacy of RXDX-101 in patients with locally Advanced or Metastatic Cancer Ensayo Clinico para investigar la seguridad y eficacia de RXDX-101 in pacientes con Cáncer metastásico o localmente avanzado
Primary Objective of Phase 1 Dose Escalation: The primary objective of the Phase 1 dose escalation segment is to determine the first cycle dose-limiting toxicities (DLTs), maximum tolerated dose (MTD)...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Ignyta, Inc
Update Il y a 4 ans
Study of Tumor Alterations Responsive to Targeting Receptor Kinases-2
To determine the objective response rate of entrectinib, as assessed by BICR, in each patient population basket of solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene rearrangement
Country
None
organs
None
Specialty
None
unknown
More information